Greg Madison of Shield Therapeutics: Agreement with Viatris enables opportunity to scale Accrufer® into a $2 billion market
If you find this podcast useful please give it a rating and review on iTunes by clicking here
Greg Madison CEO of explains how their agreement with Viatris and new funds allows them to scale Accrufer® to make it the oral iron of choice in the US and take advantage of a $2 billion market opportunity.
Highlights
Shield Therapeutics plc, a commercial stage pharmaceutical company focused on the commercialization of Accrufer®/Feraccru® (ferric maltol), today announced that it has entered into an exclusive, multi-year agreement with Viatris Inc. (NASDAQ: VTRS), a global healthcare company, to co-commercialize Accrufer® (ferric maltol), a novel, oral iron therapy differentiated from other conventional irons by its efficacy, well-tolerated formulation, and broad indication, in the United States.
The oral iron market in the United States is an estimated US$2 billion market opportunity, and Accrufer® is the only FDA approved oral iron to treat iron deficiency, with or without anemia. This new collaboration expands the commercial footprint and resources for Accrufer®, as the brand aspires to be the oral iron of choice in the US market. The collaboration will result in a 100 person sales team who will promote Accrufer® to over 12,000 Health Care Professionals who write the majority of oral iron prescriptions. In addition, Shield and Viatris will also deploy additional resources in digital marketing, market access, distribution and commercial operations via a shared cost model.
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.